{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:45:58Z","timestamp":1782585958564,"version":"3.54.5"},"reference-count":142,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Second-generation influenza vaccines include high-dose inactivated vaccine, recombinant vaccine, and MF-59 adjuvanted inactivated vaccine. In 2022, the US Advisory Committee on Immunization Practices issued a preferential recommendation for second-generation vaccines in adults aged \u226565 years. A substantial proportion of individuals aged &amp;lt;65 years who are immunocompromised may be insufficiently protected by first-generation standard-dose inactivated influenza vaccines. This scoping review assessed evidence on the immunogenicity, efficacy, effectiveness, and safety of influenza vaccines in immunocompromised populations to potentially inform public health decision making and identify research gaps for improved influenza control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In May 2026, we searched MEDLINE for studies published since 2014 that reported on vaccine effectiveness, efficacy, and immune response to influenza vaccination in individuals who were immunocompromised. Outcomes related to immunogenicity, clinical protection, and safety were assessed for first- and second-generation vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our search strategy identified 1239 articles, of which 112 met inclusion criteria. Among these, 69 focused on first-generation standard-dose influenza vaccines, 31 on second-generation vaccines, and 12 included both generations. Most studies (86%) reported immunogenicity data, while only 19% reported efficacy of effectiveness results. Few studies reported higher immunogenicity with second-generation vaccines and following a booster dose. Current evidence of second-generation influenza vaccine effectiveness was limited and inconsistent. No safety concerns were reported with first- and second-generation influenza vaccines among persons who were immunosuppressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We describe current evidence on influenza vaccine response, vaccine effectiveness, and vaccine safety in persons who are immunocompromised. The review highlights the lack of evidence supporting enhanced effectiveness of second-generation influenza vaccines in persons who are immunocompromised, although immunogenicity data and data from nonimmunocompromised populations support the potential benefits among persons aged &amp;lt;65 years who are immunocompromised.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag360","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:47:40Z","timestamp":1781178460000},"source":"Crossref","is-referenced-by-count":0,"title":["Influenza Vaccines for Persons Who Are Immunocompromised: A Scoping Review of the Literature"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9774-9095","authenticated-orcid":false,"given":"Charles-Antoine","family":"Guay","sequence":"first","affiliation":[{"name":"Centre de Recherche de l\u2019Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec - Universit\u00e9 Laval , Qu\u00e9bec City, Qu\u00e9bec ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 Laval , Qu\u00e9bec City, Qu\u00e9bec ,","place":["Canada"]},{"name":"D\u00e9partement des Sciences de la Sant\u00e9 Communautaire, Facult\u00e9 de M\u00e9decine et des Sciences de la Sant\u00e9, Universit\u00e9 de Sherbrooke , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Flannery","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026062714214062800_ofag360-B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026062714214062800_ofag360-B2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/cid\/ciad627","article-title":"Influenza hospitalization burden by subtype, age, comorbidity, and vaccination status: 2012\u20132013 to 2018\u20132019 seasons, Quebec, Canada","volume":"78","author":"Carazo","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz225","article-title":"Age-related differences in hospitalization rates, clinical presentation, and outcomes among older adults hospitalized with influenza\u2014US Influenza Hospitalization Surveillance Network (FluSurv-NET)","volume":"6","author":"Czaja","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026062714214062800_ofag360-B4","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/cid\/ciz638","article-title":"Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011\u20132015","volume":"70","author":"Collins","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3201\/eid2608.191493","article-title":"Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States","volume":"26","author":"Patel","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2026062714214062800_ofag360-B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126839","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2023","volume":"51","author":"Taaffe","year":"2025","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jis487","article-title":"Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology","volume":"206","author":"Beck","year":"2012","journal-title":"J Infect Dis"},{"key":"2026062714214062800_ofag360-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100327","article-title":"High-dose influenza vaccine in older adults by age and seasonal characteristics: systematic review and meta-analysis update","volume":"14","author":"Lee","year":"2023","journal-title":"Vaccine X"},{"key":"2026062714214062800_ofag360-B9","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126316","article-title":"Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019\u20132020 US influenza season","volume":"42","author":"Imran","year":"2024","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52677","article-title":"Recombinant vs egg-based quadrivalent influenza vaccination for nursing home residents: a cluster randomized trial","volume":"8","author":"McConeghy","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026062714214062800_ofag360-B11","first-page":"1","article-title":"Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007","volume":"56","author":"Fiore","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"2026062714214062800_ofag360-B12","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2026062714214062800_ofag360-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022\u201323 influenza season","volume":"71","author":"Grohskopf","year":"2022","journal-title":"MMWR Recomm Rep"},{"key":"2026062714214062800_ofag360-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024\u201325 influenza season","volume":"73","author":"Grohskopf","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"2026062714214062800_ofag360-B15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026062714214062800_ofag360-B16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076335","article-title":"Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness","volume":"384","author":"Garritty","year":"2024","journal-title":"BMJ"},{"key":"2026062714214062800_ofag360-B17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"2026062714214062800_ofag360-B18","author":"Food and Drug Administration"},{"key":"2026062714214062800_ofag360-B19","author":"World Health Organization"},{"key":"2026062714214062800_ofag360-B20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/vaccines7040215","article-title":"Mapping host-related correlates of influenza vaccine-induced immune response: an umbrella review of the available systematic reviews and meta-analyses.","volume":"7","author":"Domnich","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"2026062714214062800_ofag360-B21","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13604","article-title":"Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: a systematic review","volume":"51","author":"Spagnolo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2026062714214062800_ofag360-B22","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1080\/03007995.2017.1329140","article-title":"Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis","volume":"33","author":"Huang","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2026062714214062800_ofag360-B23","article-title":"Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026062714214062800_ofag360-B24","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.vaccine.2022.02.027","article-title":"Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: a systematic review and meta-analysis of 1429 patients","volume":"40","author":"M\u00fcller","year":"2022","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.122852","article-title":"Immunogenicity and safety of vaccines in multiple sclerosis: a systematic review and meta-analysis","volume":"456","author":"Marantos","year":"2024","journal-title":"J Neurol Sci"},{"key":"2026062714214062800_ofag360-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102698","article-title":"Immunogenicity of the influenza vaccine in multiple sclerosis patients: a systematic review and meta-analysis","volume":"48","author":"Nguyen","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2026062714214062800_ofag360-B27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cam4.596","article-title":"Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer","volume":"5","author":"Kotecha","year":"2016","journal-title":"Cancer Med"},{"key":"2026062714214062800_ofag360-B28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/pbc.24893","article-title":"Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy","volume":"61","author":"Ottoffy","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2026062714214062800_ofag360-B29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4137\/CMO.S13774","article-title":"Influenza vaccination in cancer patients undergoing systemic therapy","volume":"8","author":"Shehata","year":"2014","journal-title":"Clin Med Insights Oncol"},{"key":"2026062714214062800_ofag360-B30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690940","article-title":"Baseline CD3+CD56+ (NKT-like) cells and the outcome of influenza vaccination in children undergoing chemotherapy","volume":"12","author":"Leibinger","year":"2021","journal-title":"Front Immunol"},{"key":"2026062714214062800_ofag360-B31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/apa.17070","article-title":"Adequate immune responses to vaccines after chemotherapy for leukaemia diagnosed in childhood","volume":"113","author":"\u00d3skarsson","year":"2024","journal-title":"Acta Paediatr"},{"key":"2026062714214062800_ofag360-B32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003428","article-title":"Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study","volume":"9","author":"Walti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062714214062800_ofag360-B33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/vaccines12111224","article-title":"Immunogenicity and antibody persistence of the inactivated quadrivalent influenza vaccine in pediatric patients post-chemotherapy or allogeneic hematopoietic stem cell transplantation versus healthy controls","volume":"12","author":"Hur","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026062714214062800_ofag360-B34","first-page":"5411","article-title":"Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study","volume":"28","author":"Ayoola","year":"2020","journal-title":"Support Care Cancer"},{"key":"2026062714214062800_ofag360-B35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-020-05815-y","article-title":"Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting","volume":"184","author":"Joona","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026062714214062800_ofag360-B36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/cid\/ciz1092","article-title":"Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors","volume":"71","author":"Keam","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncr.30468","article-title":"Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles","volume":"123","author":"Keam","year":"2017","journal-title":"Cancer"},{"key":"2026062714214062800_ofag360-B38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/21645515.2016.1246094","article-title":"Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy","volume":"13","author":"Nakashima","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2026062714214062800_ofag360-B39","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jiac.2023.07.008","article-title":"Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: a single-center prospective cohort study","volume":"29","author":"Nakashima","year":"2023","journal-title":"J Infect Chemother"},{"key":"2026062714214062800_ofag360-B40","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/neuonc\/nou051","article-title":"Influenza vaccine immunogenicity in patients with primary central nervous system malignancy","volume":"16","author":"Strowd","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026062714214062800_ofag360-B41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/COC.0000000000000257","article-title":"Immunogenicity of influenza vaccination in patients with cancer","volume":"41","author":"Waqar","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"2026062714214062800_ofag360-B42","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/01.TP.0000438024.10375.2d","article-title":"Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients","volume":"97","author":"Cowan","year":"2014","journal-title":"Transplantation"},{"key":"2026062714214062800_ofag360-B43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/infdis\/jiv015","article-title":"Effect of immunosuppression on T-helper 2 and B-cell responses to influenza vaccination","volume":"212","author":"Egli","year":"2015","journal-title":"J Infect Dis"},{"key":"2026062714214062800_ofag360-B44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/tri.12237","article-title":"Antibody persistence 1 year after pandemic H1N1 2009 influenza vaccination and immunogenicity of subsequent seasonal influenza vaccine among adult organ transplant patients","volume":"27","author":"Felldin","year":"2014","journal-title":"Transpl Int"},{"key":"2026062714214062800_ofag360-B45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.trim.2019.01.001","article-title":"Kinetics of antibody response to influenza vaccination in renal transplant recipients","volume":"53","author":"Gangappa","year":"2019","journal-title":"Transpl Immunol"},{"key":"2026062714214062800_ofag360-B46","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/ajt.16503","article-title":"Natural influenza infection produces a greater diversity of humoral responses than vaccination in immunosuppressed transplant recipients","volume":"21","author":"Hirzel","year":"2021","journal-title":"Am J Transplant"},{"key":"2026062714214062800_ofag360-B47","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4103\/1319-2442.164556","article-title":"Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis","volume":"26","author":"Karbasi-Afshar","year":"2015","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2026062714214062800_ofag360-B48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jinf.2021.07.010","article-title":"Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: a randomized controlled trial","volume":"83","author":"Mombelli","year":"2021","journal-title":"J Infect"},{"key":"2026062714214062800_ofag360-B49","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/cid\/ciw855","article-title":"Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial","volume":"64","author":"Cordero","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B50","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1016\/j.vaccine.2016.05.021","article-title":"Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies","volume":"34","author":"H\u00e9quet","year":"2016","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B51","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1080\/21645515.2016.1201623","article-title":"Effect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: a systematic literature review and meta-analysis","volume":"12","author":"Liao","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2026062714214062800_ofag360-B52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/TP.0000000000003702","article-title":"An open-label randomized controlled parallel-group pilot study comparing the immunogenicity of a standard-, double-, and booster-dose regimens of the 2014 seasonal trivalent inactivated influenza vaccine in kidney transplant recipients","volume":"106","author":"Odongo","year":"2022","journal-title":"Transplantation"},{"key":"2026062714214062800_ofag360-B53","doi-asserted-by":"crossref","first-page":"1040.e11","DOI":"10.1016\/j.cmi.2015.07.014","article-title":"Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe","volume":"21","author":"P\u00e9rez-Romero","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2026062714214062800_ofag360-B54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/TP.0000000000000209","article-title":"B-sides serologic markers of immunogenicity in kidney transplanted patients: report from 2012\u20132013 flu vaccination experience","volume":"98","author":"Rinaldi","year":"2014","journal-title":"Transplantation"},{"key":"2026062714214062800_ofag360-B55","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/QAD.0000000000001774","article-title":"Impact of aging and HIV infection on serologic response to seasonal influenza vaccination","volume":"32","author":"Pallikkuth","year":"2018","journal-title":"AIDS"},{"key":"2026062714214062800_ofag360-B56","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/jmv.24351","article-title":"Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine","volume":"88","author":"Souza","year":"2016","journal-title":"J Med Virol"},{"key":"2026062714214062800_ofag360-B57","doi-asserted-by":"crossref","DOI":"10.1038\/srep26478","article-title":"HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation","volume":"6","author":"Wheatley","year":"2016","journal-title":"Sci Rep"},{"key":"2026062714214062800_ofag360-B58","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1128\/JVI.00285-16","article-title":"Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine","volume":"90","author":"Kristensen","year":"2016","journal-title":"J Virol"},{"key":"2026062714214062800_ofag360-B59","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/cid\/civ884","article-title":"Randomized controlled trial to compare immunogenicity of standard-dose intramuscular versus intradermal trivalent inactivated influenza vaccine in HIV-infected men who have sex with men in Bangkok, Thailand","volume":"62","author":"Garg","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B60","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1016\/j.vaccine.2023.05.055","article-title":"Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults","volume":"41","author":"Liu","year":"2023","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B61","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0956462415594061","article-title":"Long-term seroprotective response of trivalent seasonal influenza vaccine in HIV-infected children, regardless of immunogenicity before immunisation","volume":"27","author":"Moolasart","year":"2016","journal-title":"Int J STD AIDS"},{"key":"2026062714214062800_ofag360-B62","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/21645515.2015.1076599","article-title":"Safety and immunogenicity of influenza vaccine among HIV-infected adults: conventional vaccine vs intradermal vaccine","volume":"12","author":"Seo","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2026062714214062800_ofag360-B63","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/21645515.2016.1246636","article-title":"Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore","volume":"13","author":"Lau","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2026062714214062800_ofag360-B64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/nep.12416","article-title":"Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"20","author":"Jeffs","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"2026062714214062800_ofag360-B65","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","article-title":"Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study","volume":"20","author":"Olberg","year":"2014","journal-title":"Mult Scler"},{"key":"2026062714214062800_ofag360-B66","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur J Neurol"},{"key":"2026062714214062800_ofag360-B67","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cells12091243","article-title":"Immune response to seasonal influenza vaccination in multiple sclerosis patients receiving cladribine","volume":"12","author":"Rolfes","year":"2023","journal-title":"Cells"},{"key":"2026062714214062800_ofag360-B68","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"2026062714214062800_ofag360-B69","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12969-021-00518-0","article-title":"Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study","volume":"19","author":"Jensen","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062714214062800_ofag360-B71","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"key":"2026062714214062800_ofag360-B72","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026062714214062800_ofag360-B73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12969-017-0190-0","article-title":"Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay","volume":"15","author":"Camacho-Lovillo","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062714214062800_ofag360-B74","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.vaccine.2019.10.081","article-title":"Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab","volume":"38","author":"Furer","year":"2020","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B75","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12969-025-01099-y","article-title":"Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response","volume":"23","author":"Gyori","year":"2025","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062714214062800_ofag360-B76","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026062714214062800_ofag360-B77","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s12185-016-2163-3","article-title":"Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at &gt;1 year after undergoing allogeneic hematopoietic stem cell transplantation","volume":"105","author":"Fukatsu","year":"2017","journal-title":"Int J Hematol"},{"key":"2026062714214062800_ofag360-B78","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/infdis\/jiab391","article-title":"Association of host factors with antibody response to seasonal influenza vaccination in allogeneic hematopoietic stem cell transplant patients","volume":"225","author":"Linnik","year":"2022","journal-title":"J Infect Dis"},{"key":"2026062714214062800_ofag360-B79","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1456","article-title":"Robust immunity to influenza vaccination in haematopoietic stem cell transplant recipients following reconstitution of humoral and adaptive immunity","volume":"12","author":"Zhang","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"2026062714214062800_ofag360-B80","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41409-019-0728-5","article-title":"Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant","volume":"55","author":"Ryan","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2026062714214062800_ofag360-B81","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3109\/00365521.2014.928902","article-title":"Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy","volume":"50","author":"B\u00e1lint","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2026062714214062800_ofag360-B82","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00535-015-1042-7","article-title":"Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial","volume":"50","author":"Matsumoto","year":"2015","journal-title":"J Gastroenterol"},{"key":"2026062714214062800_ofag360-B83","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","article-title":"Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial","volume":"22","author":"deBruyn","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026062714214062800_ofag360-B84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/vaccines8030455","article-title":"High immunogenicity to influenza vaccination in Crohn's disease patients treated with ustekinumab","volume":"8","author":"Doornekamp","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2026062714214062800_ofag360-B85","article-title":"The immunogenicity of the influenza, pneumococcal, and hepatitis B vaccines in patients with inflammatory bowel disease treated with vedolizumab","volume":"2","author":"Harrington","year":"2020","journal-title":"Crohns Colitis 360"},{"key":"2026062714214062800_ofag360-B86","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/ecco-jcc\/jjv152","article-title":"Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and\/or biologics: a two-year prospective study","volume":"9","author":"Launay","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2026062714214062800_ofag360-B87","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ibd\/izx101","article-title":"Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy","volume":"24","author":"Shirai","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026062714214062800_ofag360-B88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12879-015-1161-z","article-title":"Immunogenicity and safety of intradermal influenza vaccine in immunocompromized patients: a meta-analysis of randomized controlled trials","volume":"15","author":"Pileggi","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2026062714214062800_ofag360-B89","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.vaccine.2016.04.053","article-title":"Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection","volume":"34","author":"Hakim","year":"2016","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B90","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/jcm8050590","article-title":"Alternative-dose versus standard-dose trivalent influenza vaccines for immunocompromised patients: a meta-analysis of randomised control trials","volume":"8","author":"Lai","year":"2019","journal-title":"J Clin Med"},{"key":"2026062714214062800_ofag360-B91","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jinf.2021.08.028","article-title":"Clinical efficacy and safety of high dose trivalent influenza vaccine in adults and immunosuppressed populations\u2014a systematic review and meta-analysis","volume":"83","author":"Weissman","year":"2021","journal-title":"J Infect"},{"key":"2026062714214062800_ofag360-B92","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/pbc.24863","article-title":"Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia","volume":"61","author":"McManus","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2026062714214062800_ofag360-B93","first-page":"176","article-title":"Immunogenicity of high-dose influenza vaccination in patients with primary central nervous system malignancy","volume":"5","author":"Strowd","year":"2018","journal-title":"Neurooncol Pract"},{"key":"2026062714214062800_ofag360-B94","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ajt.13960","article-title":"Heterologous immune responses to influenza vaccine in kidney transplant recipients","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"2026062714214062800_ofag360-B95","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/infdis\/jiz471","article-title":"Cell-mediated immune responses after influenza vaccination of solid organ transplant recipients: secondary outcomes analyses of a randomized controlled trial","volume":"221","author":"L\u2019Huillier","year":"2020","journal-title":"J Infect Dis"},{"key":"2026062714214062800_ofag360-B96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/cid\/ciad477","article-title":"Immunogenicity of high-dose versus MF59-adjuvanted versus standard influenza vaccine in solid organ transplant recipients: the Swiss\/Spanish trial in solid organ transplantation on prevention of influenza (STOP-FLU trial)","volume":"78","author":"Mombelli","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B97","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/petr.12419","article-title":"Randomized, double-blind comparison of standard-dose vs high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients","volume":"19","author":"GiaQuinta","year":"2015","journal-title":"Pediatr Transplant"},{"key":"2026062714214062800_ofag360-B98","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/TP.0000000000000861","article-title":"Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients","volume":"100","author":"Kumar","year":"2016","journal-title":"Transplantation"},{"key":"2026062714214062800_ofag360-B99","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2018.08.057","article-title":"Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: a randomized controlled trial","volume":"36","author":"Mombelli","year":"2018","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B100","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/cid\/cix1082","article-title":"A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0332346","article-title":"Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates","volume":"20","author":"Polishchuk","year":"2025","journal-title":"PLoS One"},{"key":"2026062714214062800_ofag360-B102","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3018(19)30322-4","article-title":"Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial","volume":"7","author":"Nunes","year":"2020","journal-title":"Lancet HIV"},{"key":"2026062714214062800_ofag360-B103","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/tid.12382","article-title":"Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients","volume":"17","author":"Ambati","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"2026062714214062800_ofag360-B104","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1093\/infdis\/jiae454","article-title":"Immunogenicity and reactogenicity of high- or standard-dose influenza vaccine in a second consecutive influenza season","volume":"231","author":"Bahakel","year":"2025","journal-title":"J Infect Dis"},{"key":"2026062714214062800_ofag360-B105","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bbmt.2015.12.003","article-title":"Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients","volume":"22","author":"Halasa","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026062714214062800_ofag360-B106","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/cid\/ciad534","article-title":"The durability of antibody responses of two doses of high-dose relative to two doses of standard-dose inactivated influenza vaccine in pediatric hematopoietic cell transplant recipients: a multi-center randomized controlled trial","volume":"78","author":"Schuster","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B107","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/cid\/ciad458","article-title":"Comparison of two high-dose versus two standard-dose influenza vaccines in adult allogeneic hematopoietic cell transplant recipients","volume":"77","author":"Thomas","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B108","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.vaccine.2015.12.037","article-title":"Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: a pilot randomized clinical trial","volume":"34","author":"Jamshed","year":"2016","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B109","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1016\/j.vaccine.2020.04.002","article-title":"High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: results of the DMID 10-0076 randomized clinical trial","volume":"38","author":"Stapleton","year":"2020","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B110","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026062714214062800_ofag360-B111","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.ajkd.2022.01.425","article-title":"Seroresponse to inactivated and recombinant influenza vaccines among maintenance hemodialysis patients","volume":"80","author":"Manley","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026062714214062800_ofag360-B112","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3389\/fimmu.2020.01876","article-title":"Assessment of immunogenicity of adjuvanted quadrivalent inactivated influenza vaccine in healthy people and patients with common variable immune deficiency","volume":"11","author":"Kostinova","year":"2020","journal-title":"Front Immunol"},{"key":"2026062714214062800_ofag360-B113","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106538","article-title":"High-dose versus standard-dose influenza vaccine for immunocompromised patients: a systematic review and meta-analysis of randomised clinical trials","volume":"91","author":"Rivera-Izquierdo","year":"2025","journal-title":"J Infect"},{"key":"2026062714214062800_ofag360-B114","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.19.00354","article-title":"Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing data from Ontario, Canada","volume":"37","author":"Blanchette","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026062714214062800_ofag360-B115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ekir.2023.10.031","article-title":"Influenza vaccine administration and effectiveness among children and adults with glomerular disease","volume":"9","author":"Glenn","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026062714214062800_ofag360-B116","doi-asserted-by":"crossref","first-page":"e4353","DOI":"10.1093\/cid\/ciaa1927","article-title":"Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in immunocompromised adults","volume":"73","author":"Hughes","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B117","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2354013","article-title":"Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017\u20132018","volume":"20","author":"Hughes Kramer","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026062714214062800_ofag360-B118","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/infdis\/jiaa757","article-title":"Influenza vaccine failure associated with age and immunosuppression","volume":"224","author":"Kimball","year":"2021","journal-title":"J Infect Dis"},{"key":"2026062714214062800_ofag360-B119","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2","author":"Bitterman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026062714214062800_ofag360-B120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhin.2017.12.003","article-title":"Clinical efficacy of seasonal influenza vaccination: characteristics of two outbreaks of influenza A(H1N1) in immunocompromised patients","volume":"99","author":"Helantera","year":"2018","journal-title":"J Hosp Infect"},{"key":"2026062714214062800_ofag360-B121","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35574","article-title":"Influenza vaccine effectiveness in immunocompromised patients with cancer: a Danish nationwide register-based cohort study","volume":"131","author":"Amdisen","year":"2025","journal-title":"Cancer"},{"key":"2026062714214062800_ofag360-B122","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/vaccines10071144","article-title":"The protective effects of influenza vaccination in elderly patients with breast cancer in Taiwan: a real-world evidence-based study","volume":"10","author":"Wu","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2026062714214062800_ofag360-B123","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1111\/ajt.17055","article-title":"Effect of influenza vaccination in solid organ transplant recipients: a nationwide population-based cohort study","volume":"22","author":"Harboe","year":"2022","journal-title":"Am J Transplant"},{"key":"2026062714214062800_ofag360-B124","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/ajt.13285","article-title":"Outbreak of influenza A(H1N1) in a kidney transplant unit\u2013protective effect of vaccination","volume":"15","author":"Helantera","year":"2015","journal-title":"Am J Transplant"},{"key":"2026062714214062800_ofag360-B125","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.transproceed.2018.02.186","article-title":"Effect of influenza vaccine in patients with kidney transplant","volume":"50","author":"Tsujimura","year":"2018","journal-title":"Transplant Proc"},{"key":"2026062714214062800_ofag360-B126","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1093\/rheumatology\/keaa078","article-title":"Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs","volume":"59","author":"Nakafero","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026062714214062800_ofag360-B127","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/cid\/ciy792","article-title":"Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: a cross-sectional, prospective, observational study","volume":"68","author":"Pi\u00f1ana","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026062714214062800_ofag360-B128","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02644-x","article-title":"Influenza virus vaccination in pediatric nephrotic syndrome significantly reduces rate of relapse and influenza virus infection as assessed in a nationwide survey","volume":"11","author":"Ishimori","year":"2021","journal-title":"Sci Rep"},{"key":"2026062714214062800_ofag360-B129","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002619","article-title":"Influenza vaccine indication during therapy with immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)","volume":"9","author":"Bersanelli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062714214062800_ofag360-B130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2020.04.008","article-title":"Host immune response-inspired development of the influenza vaccine","volume":"125","author":"Choi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026062714214062800_ofag360-B131","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0192-0561(00)00078-3","article-title":"Mechanisms of immune dysfunction in stem cell transplantation","volume":"22","author":"Talmadge","year":"2000","journal-title":"Int J Immunopharmacol"},{"key":"2026062714214062800_ofag360-B132","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/08923973.2021.1966033","article-title":"Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs","volume":"43","author":"Parlakpinar","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2026062714214062800_ofag360-B133","article-title":"Immunosuppressive drugs modes of action","volume":"54\u201355","author":"Meneghini","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026062714214062800_ofag360-B134","doi-asserted-by":"crossref","first-page":"8264","DOI":"10.1016\/j.vaccine.2020.11.002","article-title":"Understanding immunosenescence and its impact on vaccination of older adults","volume":"38","author":"Allen","year":"2020","journal-title":"Vaccine"},{"key":"2026062714214062800_ofag360-B135","author":"BC Centre for Disease Control"},{"key":"2026062714214062800_ofag360-B136","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2026062714214062800_ofag360-B137","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1469-0691.2012.03971.x","article-title":"Vaccination of immunocompromised patients","volume":"18","author":"Ljungman","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026062714214062800_ofag360-B138","doi-asserted-by":"crossref","first-page":"500","DOI":"10.15585\/mmwr.mm7432a2","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2025\u201326 influenza season","volume":"74","author":"Grohskopf","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026062714214062800_ofag360-B139","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/vaccines8030446","article-title":"Evaluating the relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017\u20132018 influenza season","volume":"8","author":"Pelton","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2026062714214062800_ofag360-B140","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ijid.2022.07.048","article-title":"Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis","volume":"122","author":"Domnich","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026062714214062800_ofag360-B141","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1186\/s12889-024-20903-0","article-title":"A multi-stage approach to support timely health policy decisions during crisis: the fast-track Delphi","volume":"24","author":"Velarde Creze","year":"2024","journal-title":"BMC Public Health"},{"key":"2026062714214062800_ofag360-B142","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.15585\/mmwr.mm6745a4","article-title":"Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices","volume":"67","author":"Lee","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag360\/68517831\/ofag360.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag360\/68517831\/ofag360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag360\/68517831\/ofag360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:22:15Z","timestamp":1782584535000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag360\/8706985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":142,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag360","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag360"}}